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Systematic reviews have become an increasingly popular tool to assess best evidence and have an 
established place at the top of the evidence pyramid, above individual randomised controlled trials. 
Most systematic reviews include a meta-analysis. Over recent years, the methodologies employed 
have become more complex, and we therefore review common methodological pitfalls and new 
developments in this editorial. 
 
Meta-analyses are a ‘statistical analysis that combines or integrates the results of several independent 
clinical trials considered by the analyst to the combinable’1 and provides a statistical summary 
estimate of the effectiveness (called an effect size) of one intervention/treatment versus another, for 
a given population.2 However, methods have been advanced to pool results from other study designs, 
for example, comparative observational studies for estimating an association between a risk factor 
and disease, or studies for estimating the prevalence of a disease. Meta-analyses are useful as they 
provide estimates of effect from more than one study and therefore will have increased statistical 
power (through larger sample size) and have improved estimates of precision (through smaller 
standard errors), thus yielding narrower confidence intervals for the effect estimate; therefore, the 
more certain we are that the effect estimate reflects the true effect size. Meta-analyses also help 
overcome controversies resulting from disparate results across studies and can generate new 
hypotheses to be tested in future studies. However, there are many decisions which need to be made 
before a meta-analysis is conducted as part of a systematic review. We describe some of the common 
pitfalls that authors may face below. 
 
Common pitfall 1: Missing crucial steps in the conduct of a systematic review 
 
There are five main steps in the conduct of a systematic review: i) framing the question; ii) identifying 
the literature; iii) assessing the methodological quality (or risk of bias) of the included studies using a 
validated tool appropriate to the design of the included studies; iv) synthesis of the findings and, 
where appropriate, rating of the certainty of evidence; and v) the interpretation of the findings. The 
most important step is framing the question, as the findings from a systematic review hinge on 
whether the right question was asked. Research questions of healthcare interventions should aim to 
address feasibility, appropriateness, meaningfulness, and effectiveness.2 Meta-analyses should only 
be performed, once all of the previous steps have been completed, using best method practices, such 
as comprehensive search strategies, which include searching electronic databases and grey literature, 
for example, conference proceedings abstracts, theses/dissertations, working/government reports, 
and contact with leading expert and/or relevant manufacturers of the intervention. It is also important 
to screen trial registries as positive studies are more likely to be published than negative ones, 
particularly in full text form. Whilst this can be very time consuming in practice, it is important that 
the searches are exhaustive and without language restrictions so that all of the relevant literature is 
identified. Furthermore, it is important that search strategies are reported in sufficient detail in the 
manuscript to allow replication. Two authors should be independently involved in the screening of 
papers for eligibility, data extraction, and the assessment of methodological quality (or risk of bias), 
to minimise errors. 
 
Common pitfall 2: Use of surrogate outcome measures 
 
Authors should be aware of apparent confirmatory systematic reviews, which are solely based on 
surrogate outcome measures or short-term outcome measures, rather than clinically important 
outcomes. For example, using transepidermal water loss as a surrogate outcome for assessing barrier 
function in eczema, solely reporting the reduction in actinic keratosis as a surrogate for assessing the 
prevention of cutaneous squamous cell carcinoma, and using sensitisation to peanut as a surrogate 
for clinically diagnosed peanut allergy. The primary outcome measures of the review should be chosen 
so that both clinically and patient-orientated outcomes are included, hence the primary outcomes 
may not be what is usually measured in a study. Whilst it can be very useful to consider surrogate 
outcome measures within a review, these should only be used as secondary outcome measures, since 
there is the potential for inconsistent results to be found between surrogate and clinical outcomes.  
 
Common pitfall 3: Using heterogeneity measures to determine whether to conduct a meta-analysis  
 
Often, meta-analyses are not performed based on the results of tests or measures of heterogeneity. 
However, as the effectiveness of a healthcare intervention will differ by participants or study 
characteristics, a degree of heterogeneity can be expected. Typical reasons for heterogeneity that can 
influence the estimate of effect are differences in the clinical setting (e.g. primary care versus 
secondary care), geographical setting (low/middle income versus high income countries), length of 
follow-up, baseline characteristics (e.g. severe psoriasis versus mild to moderate psoriasis), 
comedications (e.g certain comedications allowed versus no comedication allowed) or definitions in 
clinical outcomes (for example, any eczema flare versus severe eczema flare). Other important factors 
that can lead to variations in the estimates of effect are due to differences in study designs (RCTs 
versus quasi-RCTs) or other domains of methodological quality (e.g. allocation concealment, blinding, 
or attrition bias).  
 
However, it must be noted that I2, which is a commonly used measure for determining the quantity of 
inconsistency between studies in a meta-analysis3, does not tell us how much variation there is in the 
effect estimates between studies. I2 is the proportion of variation in the meta-analysis that is due to 
study results heterogeneity (ranges from 0-100%), and therefore should be used to describe how 
much overlap there is between the 95% confidence intervals of the studies included in the meta-
analysis (for example, low I2 values indicate that there is much overlap in 95% CI). I2 values should not 
be compared between different meta-analyses since the value is dependent on the magnitude of 
sampling error within the included studies.  
 
A valid rationale for not conducting a meta-analysis would be where it was decided a priori that it did 
not make clinical sense to estimate an average intervention effect.  Therefore, if it makes clinical sense 
to perform the meta-analysis, then the analysis should be performed irrespective of the value of the 
I2 statistic. However, it is important that a thorough investigation of heterogeneity is conducted to 
explore potential reasons for why differences in estimates of effect between the studies is seen.  
 
As part of this assessment, a good first step is to re-check data entry as mistakes can happen, even 
when double data entry was used. Second, subgroup analysis can be used to explore whether the 
pooled magnitude of effect differ between specific subgroups measured at study level, for example, 
dose of treatment (high versus low), outcome definitions, and geographical setting. Subgroup analyses 
use a statistical test to assess whether differences exist in the pooled estimates. An extension to the 
subgroup analysis is meta-regression, where continuous study level factors, for example year of 
publication, can be included in the model to assess whether the effectiveness of the intervention 
varies as year of publication increases. Finally, sensitivity analyses can be used to explore whether the 
pooled results are robust when studies are restricted to those which meet specific criteria, for 
example, excluding studies with a high risk of bias for allocation concealment. Sensitivity analyses 
descriptively compare the pooled magnitude of effect between the overall meta-analysis including all 
studies and the meta-analysis restricted to studies meeting the criterion. The study level variables to 
be used in subgroup and sensitivity analyses should be pre-specified a priori in the protocol to 
minimise the chance of a false positive result. It is important to remember that subgroup and 
sensitivity analyses are observational associations, and not causal, as any observed effect could be 
due to confounding, bias or chance.  
 
Common pitfall 4: Not adhering to conduct and reporting guidelines for systematic review meta-
analyses 
For systematic reviews to be considered for publication in the British Journal of Dermatology, authors 
are encouraged register the systematic review protocol either on the International Prospective 
Register Of Systematic Reviews (PROSPERO) database (https://www.crd.york.ac.uk/prospero/) or 
published in an appropriate peer-review journal. Prospective registration avoids duplication and 
reduce opportunity for reporting bias by enabling comparison of the completed review with was 
planned in the protocol.4 Additionally, the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines5 should be adhered to when drafting the systematic review 
protocol (using PRISMA-P) and the final systematic review manuscript, to minimise the risk of not 
including pertinent information. Any changes in the methods between those reported in the protocol 
and the final systematic review need to be highlighted and fully justified. Finally, extensions to the 
PRISMA guidelines should be used for manuscripts with network meta-analyses,6 individual patient 
data meta-analyses,7 or diagnostic test accuracy meta-analyses;8 and the MOOSE guidelines should be 
used for meta-analyses of observational studies.9,10 We look forward to receiving your high quality 
systematic reviews in the BJD Evidence-Based Dermatology Section!   
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